Conduct In Vitro Screening of Interventional Agents in High Throughput Screening (HTS) Formats: High Throughput Screening to Identify HIV Inhibitors

以高通量筛选 (HTS) 形式对介入药物进行体外筛选：通过高通量筛选识别 HIV 抑制剂

• 批准号: 10925107
• 负责人: RANGAN MAITRA
• 金额: $ 22.76万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-16 至 2024-08-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10925107
• 关键词: Acquired Immunodeficiency Syndrome; Basic Science; Cells; Chemicals; Clinical Trials; Collaborations; Communities; Contracts; Development; Devices; Extramural Activities; Gene Expression; HIV; HIV Infections; In Vitro; Intervention; Investigational New Drug Application; Investigator-Initiated Research; Libraries; Licensure; National Institute of Allergy and Infectious Disease; Private Sector; Research; Resources; Services; Therapeutic; United States Food and Drug Administration; Work; high throughput screening; inhibitor; novel therapeutics; pre-clinical; product development; research clinical testing; research study; screening

Preclinical Services for HIV Therapeutics: The purpose of these Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID Division of AIDS will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The primary focus of this task order will be the identification and characterization of agent(s) with activity to block HIV infection, inhibit HIV gene expression and replication, or cure infected cells of HIV infection.

艾滋病毒治疗学的临床前服务：这些无限期交付/无限期合同的目的是为校外科学界提供研究材料和研究材料和临床前产品开发支持候选产品，这些产品从研究人员发起的研究或与私营部门或学术伙伴或学术伙伴合作中脱颖而出。工作范围包括从基础研究和初始产品发现到临床试验和/或产品许可所需的活动的活动。这些服务还可以用于支持产品发现和开发，从而导致研究新药应用（IND），研究设备豁免（IDE）和/或新药应用（NDA）申请（NDA）提交给食品和药物管理局（FDA）。 NIAID的AIDS将主要使用这些合同来更快，更有效地填补关键的发展和资源差距，并将有希望的产品推向临床测试。该任务顺序的主要重点是鉴定和表征具有活性以阻止HIV感染，抑制HIV基因的表达和复制或治愈HIV感染的感染细胞。